Pathkey Advances AI Chip Design with Chipforge Acquisition and Early Industry Deals
Pathkey.AI has completed its acquisition of Chipforge, integrating AI-driven semiconductor design technology while TrialKey clinical trial software gains traction with rising revenues. The company holds $3.41 million in cash, balancing ongoing R&D investment with early commercial progress.
- Chipforge acquisition finalised, expanding AI chip design capabilities
- MOU signed with Inturai Ventures for drone-swarm edge silicon project
- TrialKey clinical trial platform grows revenue with new contracts
- Cash position steady at $3.41 million supported by R&D tax incentives
- Ongoing R&D and platform development drive negative operating cash flow
Chipforge Acquisition Completes AI Semiconductor Expansion
Pathkey.AI Ltd (ASX:PKY) has officially closed its acquisition of Singapore-based Chipforge, marking a significant step into AI-powered semiconductor design. Chipforge's platform automates custom chip development by translating high-level design inputs into verified hardware code, drastically reducing traditional development cycles from years to months and cutting multi-million-dollar costs. This integration positions Pathkey at the forefront of agentic-AI applications beyond its clinical trial roots.
The company is actively integrating Chipforge’s teams across Singapore and Australia while expanding its platform capabilities. Chipforge’s AI-native workflow supports deployment in cloud or fully air-gapped environments, addressing critical data sovereignty and security concerns for mission-critical applications.
Early Industry Engagement Signals Commercial Potential
Further industry engagement includes participation at the 2026 Design Automation Conference in Long Beach, California, where Chipforge met prospective customers and partners. The company has also appointed a global sales consultant to accelerate commercial outreach.
TrialKey Clinical Platform Shows Revenue Growth
Pathkey’s TrialKey platform, focused on clinical trial design and optimisation, continues to build commercial momentum. The platform generated $30,000 in revenue during the quarter, including $25,000 from the initial phase of an engagement with Imunexus Therapeutics Limited and an additional $5,000 from a competitor analysis project with Armstrong Clinical. The company has bolstered its commercial efforts by appointing a business development manager and attending the 2026 BIO International Convention in San Diego.
TrialKey is also advancing its technology with development of a clinical trial scenario-optimisation engine and a natural language processing tool for real-time monitoring of public trial data. These innovations are beginning to cross-pollinate with Chipforge’s AI model development, suggesting potential synergies between the platforms.
Financial Position Reflects Investment Phase with Solid Cash Buffer
As of 30 June 2026, Pathkey held $3.41 million in cash, bolstered by approximately $870,000 from option exercises during the quarter. Despite negative operating cash flow of $352,000, the company continues to participate in R&D tax incentive programs, partially offsetting its expenditure on platform development and commercialisation efforts.
Payments to related parties totalled $143,000, mainly fees for directors and executives related to product development. The company’s cash runway extends to nearly 10 quarters based on current burn rates, providing a buffer to advance its dual-platform strategy.
Bottom Line?
Pathkey’s acquisition of Chipforge and early commercial moves position it well in AI-driven semiconductor design, but sustained investment and successful contract conversions will be critical to validate growth prospects.
Questions in the middle?
- Will the MOU with Inturai Ventures convert into a binding contract and generate meaningful revenue?
- How quickly can Chipforge’s AI platform scale to broader semiconductor customers beyond initial engagements?
- Can TrialKey’s clinical trial optimisation platform accelerate revenue growth to offset ongoing R&D costs?
